Navigation Links
iTherX Appoints Stefan Zeuzem, M.D., as Chair of Scientific and Clinical Advisory Board
Date:3/15/2011

SAN DIEGO, March 15, 2011 /PRNewswire/ -- iTherX, a pharmaceutical company dedicated to discovering and developing a new class of therapies for hepatitis C, today announced that Stefan Zeuzem, M.D., has joined the company as Chair of the Scientific and Clinical Advisory Board.  Dr. Zeuzem will lead a respected group of hepatitis thought leaders in contributing their expertise to the clinical development of iTherX's lead compound, ITX-5061, a first-in-class hepatitis C entry inhibitor.

"Stefan Zeuzem brings more than 20 years of international clinical and research leadership in hepatitis viruses, as well as liver disease and transplantation to our team. iTherX is fortunate to have Dr. Zeuzem's invaluable guidance and perspective as we advance our lead compound ITX-5061, a hepatitis C viral entry inhibitor, through clinical development," said Flossie Wong-Staal, Ph.D., Chief Scientific Officer of iTherX.  "We have established a truly dynamic and experienced scientific and clinical advisory board to bring forward this novel class of compounds.  Along with our advisors, we believe ITX-5061 has the promise of preventing the entry of the hepatitis C virus into cells while complementing existing antiviral treatment."

Dr. Zeuzem currently serves as Chief of the Department of Medicine and Professor of Medicine at the Johann Wolfgang Goethe University Hospital in Frankfurt, Germany. His clinical areas of expertise include gastroenterology, hepatology, liver transplantation, endoscopy, gastrointestinal oncology, and endocrinology. Dr. Zeuzem's current research interests include cellular physiology, molecular biology of hepatitis viruses, viral kinetics, the role of hepatitis viruses in hepatocarcinogenesis, and the stratification and optimization of antiviral treatment. After receiving his medical training from the J.W. Goethe University Medical School, the University Of Cambridge School Of Clinical Medicine (United Kingdom), and the University of Newcastle upon Tyne Medical School (United Kingdom), Dr. Zeuzem completed post-doctoral fellowships in endocrinology and gastroenterology at the University Hospital in Frankfurt and research at the Royal Victorian Infirmary in Newcastle upon Tyne, at the Max-Planck-Institute for Biophysics in Frankfurt and at Yale University Medical School in the United States. A member of numerous professional associations, Dr. Zeuzem has co-authored and authored numerous manuscripts, book chapters, and reviews, including in such prestigious scientific journals as the New England Journal of Medicine, Lancet, Gastroenterology, Hepatology, Journal of Virology, Journal of Biological Chemistry and Oncogene.

Additional members of the iTherX Scientific and Clinical Advisory Board include:

Charles Rice, Ph.D., is the Maurice R. and Corinne P. Greenberg Chair in Virology and serves as Head of the Laboratory of Virology and Infectious Disease at The Rockefeller University. He is one of the world's most accomplished virologists and a prominent figure in research on members of the Flaviviridae including hepatitis C virus. Dr. Rice received his bachelor's degree from University of California Davis in 1974 and earned his Ph.D. from California Institute of Technology in 1981. Dr. Rice has co-authored over 250 articles in the field of virology, serves as a reviewer for numerous journals, and is an editor of Journal of Virology.

Robert T. Schooley, M.D., is the Professor of Medicine and Head of the Division of Infectious Diseases at the University of California, San Diego. With more than 30 years of experience in the field of infectious disease and antiviral therapy development, he contributed to the discovery and development of antiretroviral chemotherapeutic agents including reverse transcriptase inhibitors, protease inhibitors and entry inhibitors. His current research interests include hepatitis C virus, influenza and HIV pathogenesis, and therapy and infections that cause morbidity and mortality in resource limited settings. Dr. Schooley received his medical degree from the Johns Hopkins University School of Medicine in 1974 and completed his medical house staff training at the Johns Hopkins Hospital in 1976.

Alan S. Perelson, Ph.D., is currently a Los Alamos National Laboratory Senior Fellow, as well as a member of the Science Board and external professor at the Santa Fe Institute. He is also an adjunct professor of Bioinformatics at Boston University, an adjunct professor of Biostatistics and Computational Biology at the University of Rochester and an adjunct professor of Biology at the University of New Mexico.  Dr. Perelson's areas of expertise include the modeling of infectious disease and immune responses and his current research focuses on the hepatitis C virus and modeling drug resistance to antiviral agents. Dr. Perelson received B.S. degrees in Life Science and in Electrical Engineering from MIT in 1967, and a Ph.D. in Biophysics from UC Berkeley in 1972. He has coauthored over 400 articles dealing with modeling biological systems.

About iTherX

iTherX is a pharmaceutical company focused on the discovery and development of a novel class of antiviral therapeutics that act by blocking entry of the hepatitis C virus into liver cells to halt the spread of infection.  The company's lead program, ITX-5061, is currently in Phase 1b clinical studies intended to evaluate antiviral activity and safety in patients with HCV infection.  In addition to ITX-5061, iTherX is leveraging its proprietary expertise in molecular virology and medicinal chemistry to establish a pipeline of viral entry inhibitors, with additional candidates currently undergoing preclinical testing.

BCC Partners

Karen Bergman or Susan Pietropaolo, +1.650.575.1509 or +1.845.638.6290




'/>"/>
SOURCE iTherX
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
2. Streamline Health Appoints Rick Leach as Senior Vice President and Chief Marketing Officer
3. Qforma Appoints Two New Executives
4. Xeridiem Medical Devices Appoints Renae Moomjian, Vice President, Business Development
5. CareFusion Appoints Carlos M. Nunez, M.D. as Chief Medical Officer
6. Adeona Appoints George J. Brewer, M.D., Senior Vice President of Research & Development
7. WaferGen Appoints Industry Leader Dr. Timothy J. Triche to Board of Directors
8. Kendle Appoints Martha Feller, PhD, Vice President and Global Head, Study Start-up
9. Cumberland Pharmaceuticals Appoints Tan Cheow Choon as Director of International Business
10. West Appoints Two Directors and Announces Second Quarter 2011 Dividend
11. Masters Pharmaceutical, Inc. Appoints Wayne A. Corona to President and Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... , Oct. 4, 2017 ... single-use, self-contained, illuminating medical devices, today announced regulatory ... Health Surveillance Agency (or Agência Nacional de Vigilância ... first single-use, cordless surgical retractor with integrated LED ... optimal access, illumination and exposure of a tissue ...
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
Breaking Medicine Technology:
(Date:10/13/2017)... Worth, TX (PRWEB) , ... October 13, 2017 ... ... financial planning agency serving communities in the greater Dallas, Miami, and Raleigh regions, ... young boy fighting to overcome a rare and deadly chromosome abnormality. , After ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association of Eating ... excellence for the field of eating disorders, announces the opening of early registration ... Orlando, Florida at the Omni Resort at ChampionsGate. , The annual ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
Breaking Medicine News(10 mins):